This randomized phase II trial for good-risk HPV-associated OPSCC compared reduced-dose radiation (60 Gy) with or without concurrent weekly cisplatin. The RT-only arm was accelerated at 6 fractions per week. The accelerated reduced-dose radiation alone arm failed to meet statistical conditions for PFS acceptability, whereas the CRT arm did, justifying its advancement as a study arm of NRG-HN005.

Read more